Multi-Center Study of Natural History in Atypical Parkinsonian Syndromes (MAPS-NH)
1 other identifier
observational
500
1 country
20
Brief Summary
This goal of this observational study is to clarify the variations in the natural course of atypical parkinsonian syndromes (APS, including MSA, DLB, PSP, and CBD), such as the progression rate of motor and non-motor symptoms and characteristic imaging evolution patterns. Establish a comprehensive assessment framework for APS, and develop clinical and biological databases to identify biomarkers with early predictive value.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Nov 2025
Longer than P75 for all trials
20 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
November 12, 2025
CompletedFirst Submitted
Initial submission to the registry
November 20, 2025
CompletedFirst Posted
Study publicly available on registry
September 8, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 31, 2030
ExpectedStudy Completion
Last participant's last visit for all outcomes
August 31, 2030
September 8, 2026
September 1, 2026
4.8 years
November 20, 2025
September 1, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
Natural disease progression of various atypical parkinsonian syndromes
To observe the differences in the natural disease progression of various atypical parkinsonian syndromes (APS, including MSA, DLB, PSP, and CBD), such as the progression rates of motor and non-motor symptoms and the patterns of imaging evolution. The preliminary study design involves a follow-up period of 3 years, with assessments of clinical phenotypes and/or biomarker changes every 6 months.
up to 36 months
Study Arms (1)
Atypical parkinsonian syndromes
Interventions
We did not apply any interventions; only observational research was conducted.
Eligibility Criteria
Patients diagnosed with multiple system atrophy (MSA) , dementia with Lewy bodies (DLB) , progressive supranuclear palsy (PSP) , or corticobasal degeneration (CBD) according to Chinese/international consensus diagnostic criteria . Follow-up period : 3 years , with clinical phenotypes and/or biomarkers assessed every 6 months .
You may qualify if:
- MSA : Meets the "probable MSA" criteria in the 2022 Chinese expert consensus on MSA diagnosis (MSA-P or MSA-C subtype); disease duration ≤3 years (from onset of first motor symptoms) .
- DLB : Meets "probable DLB" criteria per the 2017 McKeith diagnostic criteria; MMSE ≥18 (to exclude severe dementia confounding assessment) .
- PSP : Meets "probable PSP-Richardson syndrome" criteria per the 2017 PSP diagnostic standards; vertical gaze palsy or postural instability with duration ≤2 years .
- CBD : Meets "probable CBD" criteria per the 2019 Chinese expert consensus on corticobasal degeneration diagnosis and treatment; asymmetric cortical symptoms (apraxia/dystonia/alien limb).
You may not qualify if:
- Parkinson's disease , spinocerebellar ataxia (SCA) and other secondary autonomic failure .
- Vascular parkinsonism , Parkinsonism caused by stroke , tumor , or immune-mediated encephalitis .
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (20)
Changshu Hospital Affiliated to Nanjing University of Chinese Medicine
Changshu, Jiangsu, 215500, China
The second People's Hospital of Huai'an
Huai'an, Jiangsu, 223001, China
The First People's Hospial of Kunshan
Kunshan, Jiangsu, 215300, China
Jiangsu Province Official Hospital
Nanjing, Jiangsu, 210000, China
The Second Affiliated Hospital of Nantong University
Nantong, Jiangsu, 226000, China
Jiangsu Province (Suqian) Hospital
Suqian, Jiangsu, 223800, China
The Forth Affiliated Hospital of Soochow University
Suzhou, Jiangsu, 215000, China
The Second Affiliated Hospital of Soochow University
Suzhou, Jiangsu, 215000, China
The Second Affiliated Hospital of Xuzhou Medical University
Xuzhou, Jiangsu, 221000, China
Yancheng Third People's Hospital
Yancheng, Jiangsu, 224000, China
Affiliated Hospital of Yangzhou University
Yangzhou, Jiangsu, 225000, China
Zhangjiagang TCM Hospital Affiliated to Nanjing University of Chinese Medicine/Zhangjiagang Traditional Chinese Medicine Hospital
Zhangjiagang, Jiangsu, 215600, China
The Forth People's Hospital of Zhenjiang
Zhenjiang, Jiangsu, 212000, China
Yantai Yuhuangding Hospital
Yantai, Shandong, 264000, China
Mianyang 404 Hospital
Mianyang, Sichuan, 621000, China
Jiaxing Second Hospital
Jiaxing, Zhejiang, 314000, China
Deyang People's Hospital
Deyang, China
Changxing people' s hospital
Huzhou, China
Affiliated Hospital of Nantong University
Nantong, China
The Affiliated Hospital of Xuzhou Medical University
Xuzhou, China
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Chunfeng Liu
Second Affiliated Hospital of Soochow University
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 3 Years
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 20, 2025
First Posted
September 8, 2026
Study Start
November 12, 2025
Primary Completion (Estimated)
August 31, 2030
Study Completion (Estimated)
August 31, 2030
Last Updated
September 8, 2026
Record last verified: 2026-09
Data Sharing
- IPD Sharing
- Will not share